- RTW Venture Fund Limited announced that Abdera Therapeutics has completed its $142M Series A and Series B financing rounds in which it participated. Abdera is a privately held pre-clinical stage biopharmaceutical company leveraging antibody engineering to design and develop new precision radiopharmaceuticals for cancer. The company is building a pipeline of potentially best-in-class therapies for both clinically validated and novel targets that deliver potent radioisotopes capable of emitting alpha or beta particles to selectively destroy cancer cells.
- Greencoat UK Wind PLC announced that it has published its ESG Report for 2022 which is available on the company’s website.
Due to data protection policies, USA residents can not access our data.
Your content has been curated